文献速递心脑血管急症创伤与烧伤重症综合管理与镇静镇痛

去氨加压素对抗血小板治疗期间血小板功能障碍的影响:一项系统综述

Effect of Desmopressin on Platelet Dysfunction During Antiplatelet Therapy: A Systematic Review.
PubMed 文献 · Neurocrit Care · 2020-08-04
一句话结论系统综述显示去氨加压素在抗血小板治疗期间可改善血小板功能(生化证据),但临床获益需随机试验验证。

该系统综述检索PubMed和EMBASE(2019年8月19日检索,2020年5月2日更新)及纳入研究参考文献,共纳入22项研究(18项人体研究、4项动物研究),定性合成去氨加压素的临床与生化效应数据。结果显示,去氨加压素改善非心脏手术患者、抗血小板治疗期间发生脑出血或蛛网膜下腔出血患者以及健康个体和动物的出血时间和血小板聚集。观察性数据提示去氨加压素可能减轻脑出血或创伤性脑损伤患者的血肿扩大。作者结论认为现有数据提供去氨加压素在抗血小板治疗期间改善血小板功能的生化证据,但需随机试验评估其临床效果。

要点

  • 22项研究(18项人体、4项动物)显示去氨加压素改善抗血小板治疗期间出血时间和血小板聚集。
  • 观察性数据提示去氨加压素可能减轻脑出血或创伤性脑损伤患者的血肿扩大。
  • 作者结论认为现有数据为生化证据,需随机试验评估去氨加压素在自发性或创伤性出血及神经外科抗血小板治疗患者中的潜在临床效果。

适用人群与场景

  • 接受非心脏手术且正在使用血小板抑制剂的患者
  • 抗血小板治疗期间发生自发性或创伤性出血的患者
  • 抗血小板治疗期间发生脑出血或蛛网膜下腔出血的患者
  • 健康个体及暴露于抗血小板治疗的动物

研究设计与关键结果

  • 系统综述纳入22项研究:18项人体研究和4项动物研究,定性合成数据。
  • 去氨加压素改善非心脏手术患者、抗血小板治疗期间脑出血或蛛网膜下腔出血患者以及健康个体和动物的出血时间和血小板聚集。
  • 观察性数据提示去氨加压素可能减轻脑出血或创伤性脑损伤患者的血肿扩大。

证据类型、等级与局限

  • 证据类型:系统综述,纳入18项人体研究和4项动物研究,定性数据合成。
  • 作者结论:现有数据提供去氨加压素在抗血小板治疗期间改善血小板功能的生化证据,需随机试验评估临床效果。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为现有数据为生化证据,需随机试验评估去氨加压素在自发性或创伤性出血或神经外科抗血小板治疗患者管理中的潜在临床效果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND AND OBJECTIVE: An increasing number of patients receive antiplatelet therapy. Patients exposed to surgery while receiving platelet inhibitors hold an increased bleeding risk. Especially in neurosurgery and neurocritical care patients, bleeding and hematoma expansion are feared complications as even minor bleedings may be hazardous. The objective of this systematic review was to investigate the effect of desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) on platelet function during antiplatelet therapy in patients undergoing non-cardiac surgery, patients who experience spontaneous or traumatic hemorrhage, healthy individuals and in animals.

METHODS: Studies were identified through a systematic literature search in PubMed and EMBASE on August 19, 2019, with an update on May 2, 2020, and from reference lists of the included studies. Data on clinical and biochemical effect of DDAVP were extracted from included studies for a qualitative data synthesis.

RESULTS: In total, 22 studies were included: 18 human studies and four animal studies. Overall, DDAVP improved bleeding time and increased platelet aggregation in patients undergoing non-cardiac surgery, patients suffering intracerebral or subarachnoid hemorrhage while receiving antiplatelet therapy as well as in healthy individuals and animals exposed to antiplatelet therapy. Observational data indicate that DDAVP may mitigate hematoma expansion in patients with intracerebral hemorrhage or traumatic brain injury.

CONCLUSIONS: The present data hold biochemical evidence that DDAVP improves platelet function during antiplatelet therapy in humans and animals. The need for randomized trials is evident in order to evaluate the potential clinical effect of DDAVP in management of patients with spontaneous or traumatic hemorrhage, or undergoing neurosurgery, while receiving antiplatelet therapy.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Andersen LK, Hvas AM, Hvas CL, et al. Effect of Desmopressin on Platelet Dysfunction During Antiplatelet Therapy: A Systematic Review. Neurocrit Care. 2020. PMID: 32748210. doi:10.1007/s12028-020-01055-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。